Literature DB >> 17548931

[Treatment of osteonecrosis of the femoral head with implantation of autologous bone-marrow mononuclear cells].

Yuji Yasunaga1, Hiroshi Terayama, Takuma Yamasaki, Masakazu Ishikawa, Mitsuo Ochi.   

Abstract

Idiopathic osteonecrosis of the femoral head commonly develops during adolescence and in the prime of adulthood. In Japan, joint-preserving procedures such as transtrochanteric rotational osteotomy, femoral varus osteotomy and vascularized bone grafting are often the surgical treatments of choice. However, the results of these procedures are not necessarily satisfactory. These procedures force patients to endure longer waits for their entire treatment. In addition, it is often difficult for surgeons to choose the appropriate treatment, especially in patients who have bilateral extensive osteonecrosis. We reported transplantation of bone marrow mononuclear cells for osteonecrosis of the femoral head and short-term results.

Entities:  

Mesh:

Year:  2007        PMID: 17548931     DOI: CliCa0706910915

Source DB:  PubMed          Journal:  Clin Calcium        ISSN: 0917-5857


  3 in total

1.  Surgery trends for osteonecrosis of the femoral head: a fifteen-year multi-centre study in Japan.

Authors:  Shinya Kaneko; Yasuhiko Takegami; Taisuke Seki; Wakaba Fukushima; Takashi Sakai; Wataru Ando; Naoki Ishiguro; Nobuhiko Sugano
Journal:  Int Orthop       Date:  2020-01-23       Impact factor: 3.075

2.  Vascular endothelial growth factor/bone morphogenetic protein-2 bone marrow combined modification of the mesenchymal stem cells to repair the avascular necrosis of the femoral head.

Authors:  Xiao-Wei Ma; Da-Ping Cui; De-Wei Zhao
Journal:  Int J Clin Exp Med       Date:  2015-09-15

3.  A systematic review of the concept and clinical applications of Bone Marrow Aspirate Concentrate in Orthopaedics.

Authors:  Mohamed A Imam; Samer S S Mahmoud; James Holton; Dalia Abouelmaati; Yasser Elsherbini; Martyn Snow
Journal:  SICOT J       Date:  2017-03-06
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.